HC Wainwright Issues Optimistic Estimate for RLAY Earnings

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Equities researchers at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Relay Therapeutics in a note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.36) per share for the quarter, up from their previous estimate of ($0.38). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.59) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($1.50) EPS.

Several other equities research analysts have also weighed in on RLAY. JonesTrading upgraded Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Barclays upped their price objective on Relay Therapeutics from $21.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. The Goldman Sachs Group boosted their target price on Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Citigroup reissued an “outperform” rating on shares of Relay Therapeutics in a report on Wednesday, May 20th. Finally, Guggenheim boosted their target price on Relay Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $23.30.

Relay Therapeutics Trading Up 1.8%

RLAY stock opened at $14.43 on Thursday. Relay Therapeutics has a 1-year low of $2.83 and a 1-year high of $17.32. The firm has a market cap of $2.76 billion, a P/E ratio of -9.19 and a beta of 1.74. The business’s 50 day moving average is $12.95 and its 200-day moving average is $9.91.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.58 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Commodore Capital LP lifted its holdings in Relay Therapeutics by 27.3% during the 3rd quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock worth $88,740,000 after buying an additional 3,650,000 shares in the last quarter. Casdin Capital LLC lifted its holdings in Relay Therapeutics by 14.7% during the 4th quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock worth $110,010,000 after buying an additional 1,662,193 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Relay Therapeutics by 3.1% during the 4th quarter. Vanguard Group Inc. now owns 9,691,445 shares of the company’s stock worth $81,990,000 after buying an additional 295,701 shares in the last quarter. Bellevue Group AG lifted its holdings in Relay Therapeutics by 1.4% during the 3rd quarter. Bellevue Group AG now owns 8,345,610 shares of the company’s stock worth $43,564,000 after buying an additional 114,740 shares in the last quarter. Finally, State Street Corp lifted its holdings in Relay Therapeutics by 26.8% during the 4th quarter. State Street Corp now owns 6,426,111 shares of the company’s stock worth $54,365,000 after buying an additional 1,360,121 shares in the last quarter. 96.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Relay Therapeutics

In other news, CFO Thomas Catinazzo sold 17,717 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $12.86, for a total value of $227,840.62. Following the transaction, the chief financial officer directly owned 195,178 shares of the company’s stock, valued at $2,509,989.08. The trade was a 8.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 40,449 shares of company stock valued at $532,889. 5.04% of the stock is owned by insiders.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.